Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Press release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North… -
Story People and Culture
Full Circle: A Story of Growth, Purpose and Coming Home to Novartis
Polly Cooper, Clinical Development Function Head, UK
-
Ad hoc release
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority… -
Ad hoc release
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als… -
Press release
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido … -
Statement
Novartis withdraws EMA application for adding new indication for Pluvicto®
-
Press release
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma… -
Press release
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded… -
Story
New long term social impact and sustainability targets
Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.
-
Story Access to Healthcare
Working with communities to close gaps in heart disease and cancer care
Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.
-
Press release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,… -
Story Patient Perspectives
Managing Quality of Life with CML
How shared decision-making can support living well from the start with chronic myeloid leukemia
-
Press release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North… -
Ad hoc release
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority… -
Ad hoc release
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als… -
Press release
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido … -
Press release
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma… -
Press release
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded… -
Press release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,… -
Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta… -
Press release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated… -
Press release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence… -
Press release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,… -
Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring…
-
Ad hoc release
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority… -
Ad hoc release
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als… -
Ad hoc release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from… -
Ad hoc release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf… -
Ad hoc release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III… -
Ad hoc release
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for… -
Ad hoc release
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority… -
Ad hoc release
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +7% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +7% (kWk, +6% USD)Das Umsatzwachstum beruhte… -
Ad hoc release
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the… -
Ad hoc release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled… -
Ad hoc release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s… -
Ad hoc release
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March…
-
Statement
Novartis withdraws EMA application for adding new indication for Pluvicto®
-
Statement
Bringing breakthroughs to more patients
-
Statement
Vas Narasimhan named to 2025 TIME100 Health list
-
Statement
Europe talks health sovereignty — now it must deliver
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement
Novartis provides support for Moroccan earthquake victims
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Statement
Novartis statement on filing of Inflation Reduction Act lawsuit
-
Statement
Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Story People and Culture
Full Circle: A Story of Growth, Purpose and Coming Home to Novartis
Polly Cooper, Clinical Development Function Head, UK
-
Story
New long term social impact and sustainability targets
Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.
-
Story Access to Healthcare
Working with communities to close gaps in heart disease and cancer care
Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.
-
Story Patient Perspectives
Managing Quality of Life with CML
How shared decision-making can support living well from the start with chronic myeloid leukemia
-
Story People and Culture
Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech
The leaders behind the Novartis Innovation Lab share how they are leveraging emerging technologies to win for patients.
-
Story From Our Labs
Bringing proteins together to take cancer apart
A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer.
-
Story People and Culture
Turning personal experience into purpose-driven careers
What drives someone to dedicate their career to reimagining medicine? Three women at Novartis share their deeply personal and unique stories.
-
Story People and Culture
Supercharging R&D: How AI helps us to bring medicines to patients faster
Max leads AI innovation in pharmaceutical development at Novartis. His story reflects how cutting-edge technology is combined with human expertise for meaningful impact.
-
Story Discovery
Breaking ground in Global Health
Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery
-
Story
Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List
Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Story Discovery
What's next in Neuroscience drug discovery
A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.
-
Story Access to Healthcare Infectious Diseases
How Novartis is helping to eliminate leprosy
Leprosy is one of the world’s oldest infectious diseases – yet there are still around 200,000 cases every year1. As the only supplier of multidrug therapy, in January 2026 Novartis renewed its partnership to provide the medicine via the WHO, protecting vital access to treatment.
Novartis Financial Results - Q1 2026
Novartis announces the company’s financial results for the first quarter of 2026.
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Events
Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.
